We want to ensure optimum use of our website for you, and to continually improve our website. Therefore, we work with selected partners (e.g. Pardot). You can revoke your voluntary consent at any time. You can find further information and setting options under „Configure“ and in our data protection information.
Stockholm, August 15, 2013 – Elekta will publish its interim report for May-July 2013/14 on September 3 as per: · The report will be published at 13:00 CET · Elekta will host a telephone conference at 13.45 – 14.30 CET with Tomas Puusepp, President and CEO, and Håkan Bergström, CFO
To take part in the conference call, please dial in about five minutes in advance,
use the telephone numbers below and the access code 935720.
• UK dial-in number: +44 (0)20 7162 0077
• US dial-in number: + 1 334 323 6201
• Swedish dial-in number: +46 (0)8 5052 0110
The telephone conference will be broadcasted live online. Please use the link: http://webeventservices.reg.meeting-stream.com/81070_elekta
# # #
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.